Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients (Report)
Under the Pharmaceutical Affairs Act, people who sell pharmaceuticals without a license face fines ranging from NT$30,000 to NT$2 million (US$950 to US$63,315)
10.1210/jc.2003-032222 8 AsfergC.MogelvangR.FlyvbjergA.FrystykJ.JensenJ
Increased doses come with an upcharge of $100/month
Ongoing studies continue evaluating long-term safety, including digestive health, gallbladder events, pancreatitis risk, hydration, nutrition, and overall tolerability
The study included non-diabetic patients with asthma across three BMI categories: Overweight (BMI 25.0029.99 kg/m) Obese (BMI 30.0040.00 kg/m) Morbidly obese (BMI 40.00 kg/m) Patients initiating a GLP-1 receptor agonist were compared with matched controls without GLP-1 exposure over a three-year follow-up period
US$ 20.96
US$ 26.07
US$ 28.82
US$ 29.23
US$ 28.61
US$ 29.32
